The SUSTAIN-6 Trial (Once-Weekly Semaglutide) The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) consisted of 3297 people living with T2DM, 83% with established cardiovascular disease, receiving once-weekly semaglutide (0.5 and 1.0 mg) or placebo
This receptor-mediated mechanism differs fundamentally from small-molecule drugs that may have intracellular targets or work through different pharmacological principles
It creates misaligned incentives in the market where more expensive drugs are preferred over less expensive medicines, which is not intuitive because at the end of the day, the whole purpose of having an insurer, insurance card or a pharmacy benefit manager overlooking your insurance, your pharmacy benefits, is to cover the less expensive medicines first
Combined, they may maximize effects through different mechanismsIpamorelin is shown to deliver quick initial results while CJC-1295 may provide longer-lasting effects
Table of Contents: What is hyperhidrosis treatment
Site reactions are typically not an indication to discontinue the drug
.png)
